Showing results (151-160 of 494) with videos related to
Sort By:
Pageof 50
Journal of Cancer Policy|June 5, 2025
Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024)Kristina Jenei, Georg Hahn, Aaron S Kesselheim, et al.BMJ (Clinical Research Ed.)|September 9, 2017
Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort studySana R Mostaghim, Joshua J Gagne, Aaron S KesselheimNeurology|April 6, 2026
Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in MedicareAayan N Patel, Aaron S Kesselheim, Benjamin N RomePlos Medicine|April 13, 2011
Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaintsAaron S Kesselheim, Michelle M Mello, David M StuddertHealth Affairs (Project Hope)|August 27, 2009
Expert review of drug patent applications: improving health in the developing worldTahir Amin, Rahul Rajkumar, Priti Radhakrishnan, et al.Health Affairs (Project Hope)|March 4, 2015
Mandatory disclaimers on dietary supplements do not reliably communicate the intended issuesAaron S Kesselheim, John Connolly, James Rogers, et al.JAMA|January 23, 2014
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012Benjamin N Rome, Daniel B Kramer, Aaron S KesselheimJAMA Network Open|January 24, 2024
Characteristics of Patients Receiving Novel Muscular Dystrophy Drugs in Trials vs Routine CareDongzhe Hong, Jerry Avorn, Richard Wyss, et al.Journal of Health Politics, Policy and Law|October 6, 2023
Federal Enforcement of Pharmaceutical Fraud under the False Claims Act, 2006-2022Liam Bendicksen, Aaron S Kesselheim, C Joseph Ross DavalPageof 50